EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

June 29 2016 Adempas (riociguat) should not be used in patients with symptomatic pulmonary...

2015-16 flu vaccine effectiveness assessed in PHE report

2015-16 flu vaccine effectiveness assessed in PHE report

June 27 2016 The 2015-16 influenza vaccine effectiveness has been calculated at 57.6% in children...

Only fluoxetene considered of value in childhood major depressive disorder

Only fluoxetene considered of value in childhood major depressive disorder

June 15 2016 The bulk of commonly used antidepressants appear to have little value in the acute...

Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

May 11 2016 Initiating antiepileptic drug therapy in someone who has had a first unprovoked...

  • EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

    EMA warns against use of riociguat in PH-IIP type pulmonary hypertension

    Wednesday, 29 June 2016 10:44
  • 2015-16 flu vaccine effectiveness assessed in PHE report

    2015-16 flu vaccine effectiveness assessed in PHE report

    Tuesday, 28 June 2016 13:29
  • Only fluoxetene considered of value in childhood major depressive disorder

    Only fluoxetene considered of value in childhood major depressive disorder

    Wednesday, 15 June 2016 10:50
  • Final results from FLAME study confirms superiority of Ultibro Breezhaler over Seretide Accuhaler for reducing COPD exacerbations

    Final results from FLAME study confirms superiority of Ultibro Breezhaler over Seretide Accuhaler...

    Tuesday, 17 May 2016 12:01
  • Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

    Weigh up risk of initiating antiepileptic therapy after an initial seizure, suggests Cochrane

    Wednesday, 11 May 2016 11:32

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Clinical News

June 29 2016 New guidance for healthcare professionals to support pregnant women experiencing nausea and vomiting and hyperemesis gravidum have been published.
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...